IDEXX Laboratories, Inc. $IDXX Shares Bought by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 419.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,890 shares of the company’s stock after buying an additional 77,438 shares during the quarter. AustralianSuper Pty Ltd owned about 0.12% of IDEXX Laboratories worth $61,263,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. STF Management LP boosted its position in shares of IDEXX Laboratories by 1.3% during the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after purchasing an additional 16 shares in the last quarter. Clearstead Trust LLC boosted its holdings in IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after buying an additional 16 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after buying an additional 16 shares during the period. Moss Adams Wealth Advisors LLC grew its position in IDEXX Laboratories by 3.3% during the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after buying an additional 17 shares during the period. Finally, Stratos Wealth Partners LTD. increased its holdings in IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after buying an additional 18 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 1.0%

Shares of NASDAQ:IDXX opened at $687.74 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The stock’s fifty day simple moving average is $706.71 and its 200-day simple moving average is $658.79. The company has a market capitalization of $54.92 billion, a P/E ratio of 54.54, a P/E/G ratio of 3.72 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IDXX shares. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. BTIG Research boosted their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Finally, UBS Group raised their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $763.50.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.